Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Inclusion Criteria: * 18-75 years * Pathology: hepatocellular carcinoma * Exceed Hangzhou Criteria (Type A: diameter of tumor ≤ 8 cm or diameter of tumor and AFP ≤ 100 ng/mL; Type B: diameter of tumor \>8 cm, but 100 ng/mL \< AFP \<400 ng/mL) * No interventional therapy (TACE, RFA or I131) within 2 month * Expected survival for more than 3 months * Child-pugh grade A or grade B (≤ 7 points) * Absolute neutrophil count ≥ 1.5×10\^9 /L, Hb ≥ 9 g/L, PLT ≥ 100×10\^9 /L; TSH ≤ ULN; total bilirubin ≤ 1.5 ULN, albumin ≥ 28 g/L, AST, ALT ≤ 3 ULN; serum creatinine ≤ 1.5 ULN * ECOG: 0-2 * Patients participate in the study voluntarily and sign informed consent Exclusion Criteria: * Regional lymph node metastases or extrahepatic metastases * Allergic to Camrelizumab or Apatinib * Patients who have had or are currently complicated with other malignant tumors * Active hepatitis (hepatitis B: HBsAg positive or HBV- DNA≥10⁴copies/ml; hepatitis C: HCV antibodies and HCV-RNA positive) * Activ pulmonary tuberculosis or pulmonary tuberculosis history * Active, diagnosed, or suspected autoimmune disease (including but not limited to: uveitis, enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma) * Interstitial lung disease history or non-infectious pneumonia requiring oral or intravenous steroid therapy * Long-term systemic hormone therapy (dose \> 10mg prednisone/day) or any other form of immunosuppressive therapy * Myocardial ischemia or myocardial infarction above grade II, hypertension and inability to reach the normal range after medication (systolic blood pressure \>140mmHg, diastolic blood pressure \>90mmHg) * Abnormal coagulation function (PT\>16s, APTT\>43s, TT\>21s, Fbg\<2g/L); history of gastrointestinal bleeding within 6 months; obvious bleeding tendency or undergoing thrombolytic or anticoagulant treatment * Pregnant or lactating women * Patients who participated in other clinical trials within 1 month * Active infections which require systemic treatment * HIV positive * Other factors that may affect patients' safety or compliance